Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration
Acta Ophthalmologica · 2026-05 · 104 (3) · 296-304
DOI: 10.1111/aos.17590 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Ophthalmologica, online erschienen am 08.09.2025. Verfasst von Imadeddin Abu Ishkheidem und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Visual Acuity, Receptors, Vascular Endothelial Growth Factor, Wet Macular Degeneration. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD).
Methods
This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and February 2025. Data on best‐corrected visual acuity (BCVA), central retinal thickness (CRT), pigment epithelial detachment (PED) height, fluid status, treatment intervals, time to fluid recurrence and adverse events were collected.
Results
181 eyes (167 patients; mean age 80.4 ± 8.5 years; 67.7% female) were included, with a median follow‐up of 12.9 weeks (range 4.1–48.1). A total of 415 injections were administered (mean 2.1 ± 1.5 per eye). BCVA remained stable (baseline 0.46 ± 0.31 logMAR; post‐treatment 0.47 ± 0.37 logMAR; p = 0.18). CRT decreased significantly (−19.5 ± 47.2 μm; p < 0.001), as did PED height (−37.4 ± 68.4 μm; p < 0.001). Intraretinal fluid prevalence decreased from 34.3% to 19.3% ( p < 0.001) and subretinal fluid from 53.0% to 33.7% ( p < 0.001). The median maximal dry interval achieved was nine weeks, and analysis of interval extension showed a statistically significant mean increase of 1.27 ± 4.24 weeks overall ( p = 0.0009), particularly in eyes dry at baseline. The median time to fluid recurrence among those with reactivation was ten weeks. Higher baseline CRT predicted greater CRT reduction (−44.1 μm per 100 μm increase; p < 0.001) but shorter dry intervals. Safety was favourable, with one case (0.6% per eye; 0.2% per injection) of mild anterior uveitis and no cases of intraocular pressure elevation.
Conclusions
Switching to aflibercept 8 mg led to stable vision, significant anatomical improvements, extended treatment intervals and a favourable short‐term safety profile. Longer follow‐up is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
- Department of Ophthalmology, Region Västra Götaland, Sahlgrenska University Hospital, Mölndal, Sweden.
- Department of Ophthalmology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
ORCID-Profile: Imadeddin Abu Ishkheidem, Madeleine Zetterberg
Zitieren
APA
Abu Ishkheidem, I., Inci, E., Breimer, M., Silfverswärd, S. T., Zetterberg, M., & Grönlund, M. A. (2026). Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration. Acta Ophthalmologica, 104(3), 296-304. https://doi.org/10.1111/aos.17590
Vancouver
Abu Ishkheidem I, Inci E, Breimer M, Silfverswärd ST, Zetterberg M, Grönlund MA. Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration. Acta Ophthalmologica. 2026;104(3):296-304. doi:10.1111/aos.17590
BibTeX
@article{AbuIshkheidem2026,
author = {Abu Ishkheidem, Imadeddin and Inci, Esra and Breimer, Martin and Silfverswärd, Sofia Töyrä and Zetterberg, Madeleine and Grönlund, Marita Andersson},
title = {Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration},
journal = {Acta Ophthalmologica},
year = {2026},
volume = {104},
number = {3},
pages = {296--304},
doi = {10.1111/aos.17590}
}
EUVIMED